Essential thrombocythemia (ET) rarely causes obstruction of coronary arteries or acute myocardial infarction. Treatment of acute myocardial infarction in patients with ET may be a problem due to the important role of platelets in the pathogenesis of infarction. There is no reported case of acute myocardial infarction with essential thrombocythemia treated with a glycoprotein lIb/Illa inhibitor. In this report, a 49-year-old woman with essential thrombocythemia, admitted with a diagnosis of acute inferolateral myocardial infarction, was treated with tirofiban, a glycoprotein IIb/IIIa receptor blocker.
1. Pick RA, Glover UM, Nanfro JJ, Dubbs WF, Gibbons JA, Vieweg WVR. Acute myocardial infarction with essential thrombocythemia in a young man. Am Heart J1983; 106:406-406.
2.
2. Ghotekar LH, Dutta TK, Kumarasamy V. Essential thrombocythemia-a cause of myocardial infarction in young male. J Assoc Physicians India2001;49:473-473.
3.
3. Mitus AJ, Schafer AI. Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am1990;4:157-157.
4.
4. Imbert M, Pierre R, Thieb S, Vardimon JW, Brunning RD, Flandrin G. Essential thrombocythemia. In: Jaffe ES, Harris NL, Stein H, Vardimon JW, eds. Who Classification of Tumors: Tumors of Haematopoeitic and Lymphoid Tissues. Lyon: IARC Press, 2001:39-39.
5.
5. Scheffer MG, Michiels JJ, Roelandt JRTC. Thrombocythemia and coronary artery disease. Am Heart J1991;122:573-573.
6.
6. Kaya H, Gundogdu M, Tekin SB, Akarsu E, Bozkurt E. Essential thrombocythemia and recurrent myocardial infarction. Clin Lab Haematol2000;22:161-161.
7.
7. Douste-Blazy P, Taudou MJ, Delay M, Pris J, Sie P, Ribaut L, et al. Essential thrombocythaemia and recurrent myocardial infarction. Lancet1984;2:992-992.
8.
8. Virmani R, Popovsky MA, Roberts WC. Thrombocytosis, coronary thrombosis and acute myocardial infarction. Am JMed1979;67:498-498.
9.
9. Esteves FA, Costa FA, Lima AA, Kajita LJ, Martinez Filho EE. Essential thrombocythemia and acute myocardial infarction treated with rescue coronary angioplasty. Arq Brasil Cardiol1999;73:97-97.
10.
10. Coller BS. Platelets and thrombolytic therapy. N Engl J Med1990;322:33-33.
11.
11. Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. JAm Coll Cardiol1998;31:1466-1466.
12.
12. Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, et al. Differential sensitivity of erythrocyterich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation1989;79:920-920.
13.
13. Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, et al. Vitronectin receptor (alpha (v) beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: Implications for reperfusion in acute myocardial infarction. Circulation1997; 96:1809-1809.
14.
14. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol2002; 40:1366-1366.
